- Trials with a EudraCT protocol (280)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (20)
280 result(s) found for: Intranasal.
Displaying page 11 of 14.
EudraCT Number: 2020-001667-85 | Sponsor Protocol Number: MDL_2020_10 | Start Date*: 2020-05-15 |
Sponsor Name:Hôpital Fondation Adolphe de Rothschild | ||
Full Title: A randomized controlled trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity | ||
Medical condition: Patients with persistent hyposmia related to a SARS-CoV-2 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002167-18 | Sponsor Protocol Number: FK_0001 | Start Date*: 2017-07-31 | |||||||||||
Sponsor Name:Anna Meuronen | |||||||||||||
Full Title: INTRANASAALINEN FENTANYYLI JA S-KETAMIINI AKUUTIN KIVUN HOIDOSSA PIENTRAUMAPOTILAILLA | |||||||||||||
Medical condition: Akuutti kipu | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000295-38 | Sponsor Protocol Number: IMPEDE | Start Date*: 2020-05-27 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Phase II trial, open label, single-arm, of Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions | |||||||||||||
Medical condition: Clinical and histological evidence of Oral Premalignant Lesions (OPL) with high risk of malignant transformation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005302-44 | Sponsor Protocol Number: IPR110982 | Start Date*: 2008-02-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic r... | |||||||||||||
Medical condition: Seasonal allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007183-42 | Sponsor Protocol Number: A7881006 | Start Date*: 2009-03-20 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE IIb RANDOMISED DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-00610355 OVER 4 WEEKS IN MODERATE ASTHMATIC SUBJECTS | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000851-42 | Sponsor Protocol Number: ID-084A201 | Start Date*: 2018-07-27 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis | |||||||||||||
Medical condition: Bilateral nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003743-10 | Sponsor Protocol Number: BPL-003-201 | Start Date*: 2023-06-22 | |||||||||||
Sponsor Name:Beckley Psytech Ltd. | |||||||||||||
Full Title: A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression | |||||||||||||
Medical condition: Treatment-Resistant Depression (TRD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000267-72 | Sponsor Protocol Number: D3252C00002 | Start Date*: 2021-09-07 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps ... | ||
Medical condition: Patient with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) HU (Trial now transitioned) FR (Completed) PL (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000829-27 | Sponsor Protocol Number: LPS16747 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients | |||||||||||||
Medical condition: Chronic rhinosinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) BE (Completed) CZ (Completed) FI (Completed) HU (Completed) SE (Completed) ES (Ongoing) DK (Completed) PT (Completed) PL (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004743-22 | Sponsor Protocol Number: FFR30006 | Start Date*: Information not available in EudraCT |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc... | ||
Medical condition: Vasomotor/Idiopathic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004744-43 | Sponsor Protocol Number: FFR30007 | Start Date*: Information not available in EudraCT |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc... | ||
Medical condition: Vasomotor/Idiopathic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005048-17 | Sponsor Protocol Number: VRP080415 | Start Date*: 2009-01-27 | ||||||||||||||||
Sponsor Name:Verona Pharma Plc | ||||||||||||||||||
Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics | ||||||||||||||||||
Medical condition: Allergic Asthma and Allergic Rhinitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002859-42 | Sponsor Protocol Number: OPNT002-AUD-001 | Start Date*: 2020-01-28 | |||||||||||
Sponsor Name:Opiant Pharmaceuticals Inc | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled trial evaluating the effects of naltrexone hydrochloride nasal spray on alcohol consumption in Alcohol Use Disorder | |||||||||||||
Medical condition: Alcohol use Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005019-42 | Sponsor Protocol Number: ET16-132 | Start Date*: 2018-02-14 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas pati... | |||||||||||||
Medical condition: localised and operable soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000585-15 | Sponsor Protocol Number: CBP-201-WW003 | Start Date*: 2021-11-11 | |||||||||||
Sponsor Name:Suzhou Connect Biopharmaceuticals Ltd. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps | |||||||||||||
Medical condition: Chronic Rhinosinusitis with Nasal Polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004888-37 | Sponsor Protocol Number: FFR111158 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spr... | ||
Medical condition: Irritant (non-allergic) rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-004493-25 | Sponsor Protocol Number: FFR106080 | Start Date*: 2006-01-12 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg... | ||
Medical condition: Perennial Allergic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) EE (Completed) LV (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003310-40 | Sponsor Protocol Number: 1SPR11002 | Start Date*: 2014-01-27 | |||||||||||
Sponsor Name:Luitpold Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Single Arm, Open Label Study of the Safety, Efficacy, and Pharmacokinetics of SPRIX® (intranasal ketorolac tromethamine) in 0 to 11 year-Old Patients Undergoing Open Surgical Procedures | |||||||||||||
Medical condition: post open surgery pain (incuding but not limited to orthopedic, abdominal, thoracic, plastic/reconstructive, neurologic [spine], or urologic procedures) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005492-25 | Sponsor Protocol Number: PrEP-CS-003 | Start Date*: 2016-03-10 | |||||||||||
Sponsor Name:PrEP Biopharm Ltd. | |||||||||||||
Full Title: A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to investigate the duration of effect and evaluate further safety of PrEP-001 given prophylactically in heal... | |||||||||||||
Medical condition: Human Rhinovirus (HRV-16) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013326-17 | Sponsor Protocol Number: MI-CP208 | Start Date*: 2013-05-20 |
Sponsor Name:MedImmune, LLC | ||
Full Title: A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children | ||
Medical condition: Prophylaxis of influenza | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
